Paramore, Clark
Levine, Laurice
Bagshaw, Emma http://orcid.org/0000-0001-7208-1303
Ouyang, Chengyu
Kudlac, Amber
Larkin, Mark
Funding for this research was provided by:
bluebird bio
Article History
Accepted: 5 October 2020
First Online: 30 October 2020
Declarations
:
: bluebird bio funded this study and the preparation of this article.
: Clark Paramore is a paid employee of bluebird bio. Laurice Levine is a patient advocate who has received consulting fees from bluebird bio. Emma Bagshaw, Chengyu Ouyang, and Amber Kudlac are paid employees of Vitaccess Ltd; Mark Larkin is the CEO of Vitaccess Ltd. Vitaccess Ltd was paid by bluebird bio to run this study and develop this article. Vitaccess Ltd has also received payment from bluebird bio for consulting not directly related to this article.
: Ethics approval for this study was granted by a central independent institutional review board (Salus Institutional Review Board, Austin, TX, USA). The study was performed in accordance with the Declaration of Helsinki.
: All participants provided informed consent to take part in this study via the myThalLog app.
: All participants provided consent for the publication of de-identified, aggregated data from the study.
: Study data are available on request by contacting Vitaccess Ltd.
: AK, ML, LL, and CP contributed to the design of the study and data acquisition strategy. CO and AK led the data analysis. EB assisted with the data analysis and interpretation and drafted this manuscript. All authors reviewed the manuscript, provided feedback, and approved the version to be published.